A Delaware federal jury has determined that AstraZeneca Plc (NASDAQ:AZN) must pay Pfizer Inc (NYSE:PFE) $107.5 million in damages, concluding that AstraZeneca’s blockbuster lung cancer drug, Tagrisso, infringed on Pfizer’s Wyeth unit’s patent rights.  The jury found that AstraZeneca’s Tagrisso violated two patents held by Pfizer, which cover methods for treating cancer using the breast cancer drug Nerlynx.  Also Read: Double Good News For AstraZeneca’s Breast Cancer Drugs. Puma Biotechnology Inc (NASDAQ:PBYI), which sells Nerlynx under a license from Pfizer, was initially part of the lawsuit but is no longer a plaintiff. AstraZeneca expressed disappointment with the verdict. Citing the company’s spokesperson, Reuters ...